...
首页> 外文期刊>The Journal of Nuclear Medicine >Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors.
【24h】

Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors.

机译:(177)Lu-奥曲肽挽救疗法在支气管和胃肠道胰腺神经内分泌肿瘤患者中的应用。

获取原文
获取原文并翻译 | 示例
           

摘要

Regular therapy with the radiolabeled somatostatin analog (177)Lu-octreotate (22.2-29.6 GBq) in patients with gastroenteropancreatic or bronchial neuroendocrine tumors results in tumor remission in 46% of patients, including minor response. We present the effects of additional therapy with (177)Lu-octreotate in patients in whom progressive disease developed after an initial benefit from regular therapy. METHODS: Thirty-three patients with progressive disease after an initial radiologic or clinical response were treated with additional cycles of (177)Lu-octreotate. The intended cumulative dose of additional therapy was 14.8 GBq in 2 cycles. Responses were evaluated using Southwest Oncology Group criteria, including minor response (tumor size reduction of >or=25% and <50%). RESULTS: Median time to progression (TTP) after regular therapy was 27 mo. In 4 patients, the intended cumulative dose was not achieved (2 had progressive disease, 2 had long-lasting thrombocytopenia). Hematologic toxicity grade 3 was observed in 4 patients, and grade 4, in 1. The median follow-up time was 16 mo (range, 1-40 mo). No kidney failure or myelodysplastic syndrome was observed. Renewed tumor regression was observed in 8 patients (2 partial remission, 6 minor response), and 8 patients had stable disease. Median TTP was 17 mo. Treatment outcome was less favorable in patients with a short TTP after regular cycles. Treatment effects in patients with pancreatic neuroendocrine tumors were similar to those in patients with other gastroenteropancreatic neuroendocrine tumors. CONCLUSION: Most patients tolerated additional cycles with (177)Lu-octreotate well. None developed serious delayed adverse events. Additional cycles with (177)Lu-octreotate can have antitumor effects, but effects were less than for the regular cycles. This may be because of a worse clinical condition, more extensive tumor burden, or changed tumor characteristics. We conclude that this salvage therapy can be effective and is safe.
机译:胃肠道胰腺或支气管神经内分泌肿瘤患者常规用放射性标记的生长抑素类似物(177)Lu-奥曲肽(22.2-29.6 GBq)进行治疗可导致46%的患者肿瘤缓解,包括轻微反应。我们介绍了在常规治疗最初受益后发展为进行性疾病的患者中,(177)Lu-奥曲肽进一步治疗的效果。方法:对33例初发影像学或临床反应后进行性疾病的患者进行了其他周期的(177)Lu-奥曲肽治疗。额外治疗的预期累积剂量为2个周期的14.8 GBq。使用西南肿瘤组标准评估反应,包括轻微反应(肿瘤大小减少≥25%和<50%)。结果:常规治疗后的中位进展时间(TTP)为27 mo。 4例患者未达到预期的累积剂量(2例为进行性疾病,2例为长期血小板减少症)。在4例患者中观察到3级血液学毒性,在1例中观察到4级。中位随访时间为16 mo(范围:1-40 mo)。没有观察到肾衰竭或骨髓增生异常综合症。 8例患者出现了新的肿瘤消退(2例部分缓解,6例轻微缓解),8例病情稳定。 TTP中位数为17 mo。常规周期后TTP短的患者的治疗效果较差。胰腺神经内分泌肿瘤患者的治疗效果与其他胃肠内胰腺神经内分泌肿瘤的患者相似。结论:大多数患者耐受(177)Lu-奥曲肽良好的额外周期。没有人发生严重的延迟不良事件。含(177)Lu-奥曲肽的其他周期可能具有抗肿瘤作用,但作用小于常规周期。这可能是由于较差的临床状况,更广泛的肿瘤负担或改变的肿瘤特征所致。我们得出结论,这种抢救疗法既有效又安全。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号